Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 2269)

[noa9090]

bin ja echt erstaunt das sich auch andere mit Novavax beschäftigen.

http://www.cnbc.com/id/101025702

schöner Bericht!

Der große Shown - Down soll ja am 24-09-2013 sein. Bin gespannt was die Jungs von Novavax zu verkünden haben.

Schöner Move heute...

[E-Jack-cool_at]

Antwort auf Beitrag Nr.: 45.395.113 von E-Jack-cool_at am 06.09.13 01:17:46

stifel-nicolaus-healthcare-conference

zum 6.12. die große Überraschung im Nicolaus-Stiefel ???

http://www.wallstreet-online.de/nachricht/6319661-dgap-news-…

[E-Jack-cool_at]

bin noch dabei - nur noch 25 % Nasse
Fundamental nichts bedeutendes - ist wohl durch die Ami-Boards hochgeputscht worden.

[jostawili123]

Hallo Novavax-Fans,

seit dem 04.06.13 ein Plus von ca. 75% und kaum eine Reaktion in Germany.
Zwei Meldungen aus den letzten 3 Wochen.
Gruß jostawili123


http://www.ariva.de/news/Genetischer-Eilservice-von-GenScrip…

http://www.ariva.de/news/Genocea-Biosciences-Selected-To-Pre…

[noa9090]

Share Volume: 2,629,531
2.15$

Guter move gestern!

[noa9090]

http://www.mysmartrend.com/news-briefs/technical-analysis/no…

Es geht upppppppp!

Heutiges Volumen von 1,8 Mio Shares anstelle von 588.000 Share.

Kursziel 4,75$

[noa9090]

was steht laut Präsentation/Novavax vom November in 2013 an:

http://www.novavax.com/download/file/NVAX%20Nov%202012Lazard…

Q1/2013 - Data from Phase 2 RSV trial in women of child bearing age
Q2/2013 - Data from Phase 2 RSV trial in elderly
...

hab ich was vergessen?

[noa9090]

Hier wurde schon einige Tage nichts mehr reingestellt. Sind den alle schon im Winterschlaf...?

Das waren die letzten News im Dez/Nov.

07.12.2012 Journal Vaccine Reports Novavax' Phase I RSV Nanoparticle Vaccine Candidate Results
http://www.azonano.com/news.aspx?newsID=26130

06.12.2012 Novavax Says Phase I Clinical Trial Paper Published in Journal Vaccine
http://www.benzinga.com/news/12/12/3152945/novavax-says-phas…

03.12.2012 Novavax Publishes Preclinical Study Of RSV Protein Nanoparticle VaccineCandidate
http://www.finanznachrichten.de/nachrichten-2012-12/25352560…

03.12.2012 Novavax (NVAX) Reports Publication of Encouraging Nanoparticle Vaccine Data on RSV
http://www.streetinsider.com/Corporate+News/Novavax+%28NVAX%…

14.11.2012 'Super' Novavax: Company Outshines Stars Of Pandemic Influenza Vaccine Production
http://seekingalpha.com/article/1006621-super-novavax-compan…

[noa9090]

After hours -> Innerhalb von 8 Minuten von 2,24$ auf 2,40$ !!!!Wau!!!!

[noa9090]

Top News

Novavax (NVAX) Achieves Primary Objectives in A/H5N1 Phase 1

http://www.streetinsider.com/Corporate+News/Novavax+%28NVAX%…

Novavax, Inc. (Nasdaq: NVAX) today reported positive top-line results from two Phase 1 clinical trials of its A/H5N1 avian influenza vaccine candidate administered alone or with either one of two undisclosed adjuvants. The trials' primary objectives of demonstrating the safety and immunogenicity of varying dose-levels of the vaccine, with and without adjuvant, and the demonstration of statistically significant adjuvant effects on the immune responses were achieved. The vaccine safety was acceptable with no vaccine-related serious adverse events observed.

The two randomized, observer-blind, dose-ranging, placebo-controlled Phase 1 trials were conducted under the company's contract with the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA). The primary objectives of the two trials were to demonstrate the safety and immunogenicity of Novavax' VLP-based H5N1 vaccine candidate at varying dose-levels, with and without an adjuvant, using identical clinical study designs but with a different adjuvant in each study. A total of 666 healthy adults 18 to 49 years old were enrolled in the two trials. Each subject received intramuscular injections of vaccine or placebo at day 0 and day 21, and will be followed for 13 months following the first dose. The current data relate to safety and immune responses over the first 42 days.

The adjuvanted vaccines induced strong immunogenicity at all antigen doses tested, including the lowest (3.75 µg) dose, based on hemagglutination inhibition assay (HAI) responses against the vaccine virus at day 42.

88 to 100% of subjects receiving adjuvanted vaccine at all dose levels demonstrated serum HAI titers ≥40, a seroprotection level believed to be associated with reduced risk of disease.
86 to 100% of subjects receiving adjuvanted vaccine at all dose levels demonstrated seroconversion rates with either a four-fold rise in HAI titer or a titer of ≥1:40 from a negative baseline.
Immune responses would fulfill U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) seroprotection and seroconversion criteria for accelerated approval at the lower bound of the 95% confidence level.
When tested against another avian A/H5N1 virus different from that in the vaccine, up to 80% of subjects receiving adjuvanted vaccine developed HAI titers ≥40 against the drifted virus.